欧林生物：公司重组金葡菌疫苗目前的临床适应症是闭合性骨科手术

Core Viewpoint - The company is actively exploring the potential of its recombinant Staphylococcus aureus vaccine, which currently targets closed orthopedic surgeries, with plans to expand its applications to other clinical indications, particularly pressure ulcers, which affect over 4 million patients annually in China [2] Group 1: Vaccine Development and Market Potential - The recombinant Staphylococcus aureus vaccine has a broad market outlook as it can be extended to multiple departments related to hospital infections [2] - The company has initiated work on the second indication for the vaccine, targeting pressure ulcers, which represents a significant patient population in China [2] Group 2: Infection Statistics and Medical Needs - According to Zhi Shi Consulting, the number of MRSA infections in China is projected to reach 2.3 million cases in 2024, increasing to 2.6 million by 2035, while global MRSA cases are expected to reach 7.4 million by 2035 [2] - The high medical burden of Staphylococcus aureus infections and the growing issue of antibiotic resistance highlight the urgent need for effective vaccines, which remain unmet globally [2] Group 3: International Expansion - The company’s recombinant Staphylococcus aureus vaccine not only has a market foundation in China but also possesses potential for international expansion, with ongoing efforts to pursue related overseas collaborations [2]